1. RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors

3. Case 1 Early 1993

4. Case 1 September 1993-January 2000

5. DTC Surveillance Strategies

6. Case 1 June-August 2000

7. RAI-Refractory DTC Definition

8. RAI-Refractory DTC Use of EBRT

9. Case 1 March 2002-December 2009

10. RAI-Refractory DTC Management Options and Considerations

11. RAI-Refractory DTC Sorafenib and Temsirolimus

12. Sorafenib Common AEs

13. RAI-Refractory DTC Second-Line Therapy

14. Sorafenib and Lenvatinib Phase 3 Pivotal Trials

15. DECISION Trial Outcomes

16. SELECT Trial Outcomes

17. Case

18. Case

19. Case

20. Thyroid Cancer MAPK Pathway and Iodine Transport

21. Reversing RAI Refractoriness Selumetinib Trial

22. Case 2 May 2013-January 2014

23. Case 2 January 2014-March 2015

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)

27. References

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)